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Background: Neurofilament phosphoforms (Nf) are principal components of the axoskeleton released
during axonal injury. Cerebrospinal fluid (CSF) levels of Nf phosphoforms might be useful surrogate
markers for disability in multiple sclerosis (MS), aid in distinguishing clinical subtypes, and provide
valuable prognostic information.
Method: Thirty four patients with MS were included in a three year follow up study along with 318 controls
with other non-inflammatory neurological diseases. CSF levels of two Nf heavy chain (NfH) phosphoforms
(NfHSMI35, NfHSMI34) were quantified at baseline and three year follow up using new ELISA techniques.
Levels of NfH phosphoforms, the degree of phosphorylation (NfHSMI34:NfHSMI35 ratio), and changes in
NfH levels between baseline and follow up (DNfH) were related to the clinical phenotype (RR or SP/PP), to
three clinical scales (Kurtzke’s EDSS, ambulation index (AI), and nine hole peg test (9HPT)), and to
progression of disability.
Results: A significantly higher proportion (59%) of patients with SP/PPMS experienced an increase in
NfHSMI35 levels between baseline and follow up compared with those with RRMS (14%, p,0.05). CSF
NfHSMI34 levels at baseline were higher in patients with SP/PP (11 pg/ml) compared with RR (7 pg/ml,
p,0.05) and NfHSMI35 levels were higher at follow up in SP/PP (129 pg/ml) compared with levels below
assay sensitivity in RR (p,0.05). NfHSMI35 correlated with the EDSS (rs = 0.54, p,0.01), the AI (rs = 0.42,
p,0.05), and the 9HPT (rs = 0.59, p,0.01) at follow up.
Conclusion: The increase in NfH during the progressive phase of the disease together with the correlation
of NfHSMI35 with all clinical scales at follow up suggests that cumulative axonal loss is responsible for
sustained disability and that high NfHSMI35 levels are a poor prognostic sign.
A
xonal pathology remains the ‘‘Achilles heel’’ of
neurology. New insights from recent studies into the
‘‘axonal death cascade’’1 in multiple sclerosis (MS) are
that a high number of transected axons are already present in
acute lesions2 3 (independent of demyelination4), in patients
with a short clinical course,2 5 and as a result of electrical
activity in a hostile microenvironment.6 Axonal loss results in
atrophy of the spinal cord,7 cerebellum,8 and cortex,9 all of
which correlate with disability.7–9 In vivo quantification of
axonal damage is a key tool for monitoring and under-
standing axonal pathology in complex diseases such as MS.
Neurofilaments (Nf) constitute a major component of the
axoskeleton and are promising candidates for quantification
of axonal damage because axonal transection results in
disintegration of the distal axon membrane and Nf break-
down.10 11 Nf are released into the adjacent compartment—
that is, the cerebrospinal fluid (CSF), where they can be
measured.12 13
This prospective study was stimulated by three questions.14 15
N Can clinical subtypes of MS be distinguished on the basis of
axonal damage (disease heterogeneity16)?
N Does disability correlate with markers of axonal pathology?
N Can we predict loss of function by using biomarkers for
axonal injury?
METHODS
The present study was approved by the local ethics
committees, and written informed consent was obtained
from all patients.
Patients
A total of 34 patients from a previously reported cohort17 18
with clinically definite MS19 were followed up after three
years. A second CSF sample was available for 29 patients at
the time of study. The patients with MS were classified as
having relapsing remitting (RR, n=11), or progressive
(n=23, SP/PP) disease.20 For the CSF analysis patients with
primary (PP) and secondary (SP) progressive disease were
pooled because of small numbers. However, we will also
present a detailed subgroup analysis for classification of
patients with RR (n=10), SP (n=16) and PP (n=3) MS at
baseline and at follow up. Nine patients had been started on
treatment with interferon beta (IFNb) since recruitment in
1996. The control group consisted of 318 patients with other
non-inflammatory neurological diseases (OND) from the
National Hospital of Neurology and Neurosurgery, London,
UK. Restricted sample volume meant not all assays could be
performed on each sample and the numbers available for
each comparison are presented in table 1.
Clinical assessment
All patients were assessed within one week of each lumbar
puncture using:
Abbreviations: 9HPT, nine hole PEG test; AI, ambulation index; BSP,
brain specific proteins; CSF, cerebrospinal fluid; CTRL, control; EDSS,
Expanded Disability Status Scale; ELISA, enzyme linked immunosorbent
assay; IEF, isoelectric focusing; MS, multiple sclerosis; Nf, neurofilament;
NfH, neurofilament heavy chain; NfHSMI34, NfH detected with SMI34
antibody; NfHSMI35, NfH detected with SMI35 antibody; NfL,
neurofilament light chain; OND, other neurological diseases; PP,
primary progressive; RR, relapsing remitting; SP, secondary progressive
206
www.jnnp.com
N the Expanded Disability Status Scale (EDSS)21: ranging
from 0 (normal) to 10 (death due to multiple sclerosis)
N an ambulation index (AI): ranging from 0 (no impair-
ment) to 9 (restricted to wheelchair without independent
transfer)
N the nine hole peg test (9HPT) measuring upper limb motor
function.22
The patients were classified as clinically advancing if they
worsened on the EDSS scale by at least 1 point for an EDSS
,5.5 or at least 0.5 point for an EDSS >5.5.
Assays
Samples of CSF were obtained by routine lumbar puncture.
Aliquots of CSF were stored at 270 C˚ until assayed. Levels
of NfH phosphoforms were quantified using an in-house
enzyme linked immunosorbent assay (ELISA) technique
based on commercially available antibodies.23 This ELISA
has been optimised for the capture antibody SMI35 which
recognises a range of NfH phosphoforms (170 kDa, pI 6.2
to 210 kDa, pI 5.1). In contrast, the capture antibody
SMI34 only recognises extensively phosphorylated NfH.24
Unfortunately non-phosphorylated Nf are susceptible to
proteases,24–26 of which the CSF is a rich source. For this
reason NfHSMI32 was not measured in the present study and a
ratio of NfHSMI34 to NfHSMI35 was used to approximate the
phosphorylation status (see below). Albumin in CSF and
serum was determined by standard Laurell ‘‘rocket’’ electro-
immunoassay.
Data analysis
All statistical analyses and graphs were done using SAS
software (version 8.2, SAS Institute, Inc, Cary, NC). Because
of non-Gaussian distribution, median values and the 25–75%
interquartile ranges (IQR) were calculated. Independent
variables were compared using the non-parametric two
sample exact Wilcoxon’s rank sum test. If significance was
based on small numbers the results were checked by the
one tailed Fisher’s exact test. The linear relationship between
continuous variables was evaluated using the Spearman
correlation coefficient. Multiple correlations were corrected
using the Bonferroni method. Linear regression analysis was
performed using the least squares method.
The change in NfH levels between baseline and follow up
was expressed as the difference:
D NfH=NfHfollow up2NfHbaseline.
A positive number indicated an increase in the NfH level at
follow up. Because the interassay coefficient of variation for
NfH is 10.6%, only an increase of at least 11% was considered
for further statistical analysis.23
The phosphoform ratio is an estimate of the degree of
phosphorylation and was expressed as a cross-sectional
measure:
Ratio= (NfHSMI34/NfHSMI35)610.
A decrease in the ratio indicated an overall reduction in the
level of phosphorylation. Values with zero denominator (or
NfH at baseline and follow up below assay sensitivity) could
not be used for calculations and were excluded from this
analysis.
RESULTS
The demographic data at baseline are shown in table 1. As
expected at baseline, EDSS, AI, and 9HPT were worse in
patients with SP/PP disease than in those with RR disease.
The CSF levels of NfHSMI35baseline were higher in patients with
OND than in those with MS (p,0.001, table 2). The CSF
levels of NfHSMI34baseline were similar in both groups. No
correlations were found between the Nf phosphoforms or
their ratio and age, disease duration, time from last relapse,
relapse frequency, or the CSF albumin:serum albumin ratio
(data not shown). The shortest relapse free time was three
months at baseline in two patients. At follow up one patient
with SP/PPMS experienced a superimposed relapse two
weeks prior to the CSF sampling. There was no correlation
with time from relapse in patients with SP/PPMS or RRMS at
either sampling point.
Axonal damage accumulates in SP/PP disease
A significant increase in NfHSMI35 from baseline to follow up
was observed in a higher proportion of patients with SP/
PPMS (13/22, 59%, fig 1) when compared with patients with
RRMS (1/7, 14%, p,0.05). At follow up the median CSF level
of NfHSMI35 was higher for patients with SP/PP disease
compared with patients with RR disease (see table 2,
p,0.05).
An increase of NfHSMI34 levels was observed in a similar
proportion of patients with RR (5/7, 71%) and with SP
disease (15/22, 68%). The CSF levels of NfHSMI34baseline were
higher in patients with SP/PP than with RR disease (table 2,
p,0.05). The proportion of patients with RR (5/7, 71%) in
whom NfHSMI34 increased was higher than the proportion
with an increase in NfHSMI35 (1/7, 14%, p,0.05). The
NfHSMI34:NfHSMI35 ratio decreased in 6/7 (86%) of patients
with RR and 12/22 (55%) with SP disease. Neither of these
comparisons reached statistical significance.
Axonal injury correlates with disability
NfHSMI35 levels correlated with all three clinical scales at
follow up (fig 2). The correlation was strongest for the 9HPT
(rs= 0.59, p=0.001), followed by the EDSS (rs= 0.54,
p ,0.01), and the AI (rs= 0.42, p,0.05). The correlation
with the AI was lost after Bonferroni correction. One outlier
was observed for the 9HPT (fig 2C), but its exclusion did not
change the significance of the correlation (rs= 0.55, p,0.01).
The NfH phosphoform ratio correlated with the EDSS
Table 1 Baseline characteristics of the patients
OND Multiple sclerosis
NfHSMI35 NfHSMI34 Ratio` All SP/PP RR
Number 271 119 60 34 23 11
Female:male 155:116 61:58 32:28 15:19 11:12 4:7
Age (years)* 44.0 (1–77.9) 45.4 (34.9–52.9) 47.2 (42.5–51.5) 46.5 (42.5–51.5) 48.5 (42.5–51.5) 39.6 (34.9–47.7)
Disease duration (years)* N/A N/A N/A 14.0 (8.0–19.9) 16.0 (11.8–21.8) 8.1 (3.7–13.0)
Relapse free interval (months)* N/A N/A N/A 38.0 (8.0–96.0) 83.0 (23.5–144.5) 8.0 (3.0–38.0)
`The ‘‘ratio’’ of NfHSMI34 to NfHSMI35 was available for only a subgroup of patients due to restricted sample volume.
*Values are median (interquartile range).
Patients with SP/PP disease had a longer disease duration (p,0.05) and relapse free interval (p,0.05).
N/A, not applicable; NfHSMI34, NfH detected with SMI34 antibody; NfHSMI35, NfH detected with SMI35 antibody; OND, other neurological diseases; PP, primary
progressive; RR, relapsing remitting; SP, secondary progressive.
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(rs= 0.52, p,0.05) at follow up, but this significance was lost
after the Bonferroni correction. No significant correlation was
found between either NfH phosphoform and the change in
EDSS, AI, or 9HPT over the three year period (data not
shown). At baseline, no such correlations were found after
Bonferroni correction for either of the NfH phosphoforms or
their ratio.
Axonal injury and prognosis
The median CSF NfHSMI35 level (107 pg/ml) of patients with
MS who progressed on the EDSS scale within three years
showed a tendency to be higher compared with the median
level of those who remained stable (38 pg/ml). However, this
difference did not reach statistical significance for either the
total MS cohort or the clinical subtypes (table 3). However,
using an arbitrary cut-off level of 20 pg/ml (assay sensitivity)
on the baseline cohort, the positive predictive value of high
NfHSMI35 levels for predicting progression of patients on the
EDSS scale within three years was 100% for RRMS and 20%
for SP/PPMS with specificity of 100% and 20% and sensitivity
of 87.5% and 75%, respectively.
Three patients who had RR disease converted to SP disease
in the three year observation period. These patients had
a higher median CSF NfHSMI35baseline level (123 pg/ml) when
compared with non-converting RR patients (49 pg/ml).
Again this difference did not reach statistical significance.
Patients treated with IFNb had a lower median EDSS at
baseline (2.0 v 5.5; p,0.05) and follow up (4.0 v 4.5; p,0.05)
and were less progressive (improvement by a median of 1.5
points on the EDSS v no change; p,0.05) compared with
untreated patients. The patients treated with IFNb had lower
CSF NfHSMI34baseline levels (7 pg/ml) compared with non-treated
patients (11 pg/ml, p ,0.01). No such differences were found
for NfHSMI35baseline or the NfH phosphoform ratio.
Subgroup analysis
Since there are differences in pathogenesis between SPMS
and PPMS, particularly with reference to the degree of
inflammation, CSF levels of NfHSMI35, NfHSMI34, and their
ratio were also examined for all individual subgroups.
At baseline, there was a significant difference between
these groups for NfHSMI34 (F2,26=5.00, p,0.05). The post
hoc analysis revealed that CSF NfHSMI34 levels were higher in
patients with PP disease (mean 26.6 pg/ml) compared with
patients with SP (mean 10.19 pg/ml, p,0.01) or RR disease
(mean 9.30 pg/ml, p,0.01).
At follow up no such difference was found, probably due to
the small numbers and therefore no post hoc analysis was
performed.
DISCUSSION
The present study:
N provides evidence that accumulation of axonal damage as
estimated by serial CSF NfHSMI35 levels predominates in
SP/PPMS
N reveals a correlation between CSF levels of NfHSMI35 and
the degree of disability on three clinical scales (EDSS, AI,
9HPT)
N failed to demonstrate that CSF NfH phosphoforms might
predict the development of new disability in patients with
MS.
We interpret these findings on the basis of the epidemiolo-
gically supported hypothesis that axonal damage is a gradual
cumulative process during the course of the disease27 28 and
that loss of neurological function is a direct consequence of
axonal injury.2 14 15
Firstly, NfHSMI35 levels increased from baseline to the three
year follow up sampling in about half of our patients with
Table 2 CSF levels and ratio of NfH phosphoforms, EDSS, AI, and 9HPT at baseline in patients with MS and OND (controls),
and CSF levels and ratio of NfH phosphoforms, EDSS, AI, and 9HPT, and change over time (DNfH) at follow up in patients with
MS. Values are median (interquartile range)
OND
Multiple sclerosis
All SP/PP RR
Baseline
Number 271/119 29 19 10
NfHSMI35 (pg/ml) 260 (0–3990) 78 (80–610) 95 (25–163) 53 (11–139)
p,0.001
NfHSMI34 (pg/ml) 10 (0–12000) 9 (7–13) 11 (7–14) 7 (5–9)
p,0.05
Ratio 1.52 (0.36–5.49) 1.5 (0.6–5.4) 1.7 (0.6–5.8) 1 (0.42–3.5)
EDSS N/A 3.25 (2.0–6.5) 6.0 (3.0–7.0) 1.5 (1.0–2.0)
p,0.001
AI N/A 2 (1–7) 6 (2–8) 1 (1–1)
p,0.01
9HPT N/A 24.5 (20.5–28.5) 26.0 (24.0–30.0) 20.0 (18.0–22.0)
p,0.01
Follow up
Number – 29 19 10
NfHSMI35 (pg/ml) N/A 113 (0–178) 129 (0–209) 0 (0–120)
p,0.05
NfHSMI34 (pg/ml) N/A 50 (9–129) 30 (10–114) 51 (3–120)
Ratio N/A 3 (1–10.1) 3 (1–10.1) 5 (0–10)
DNfHSMI35 (pg/ml) N/A 4 (259–98) 82 (238–115) 249 (238–104)
DNfHSMI34 (pg/ml) N/A 37 (21–123) 22 (23–95) 51 (1–112)
EDSS N/A 4.5 (3.5–6.0) 5.5 (4.0–6.5) 3.0 (2.5–4.0)
p,0.01
AI N/A 2 (2–5) 4 (2–7) 1 (1–2)
p,0.01
9HPT N/A 23.5 (20.0–28.5) 24.5 (21.5–31.0) 20.0 (18.0–21.0)
p,0.05
9HPT, nine hole PEG test; AI, ambulation index; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; N/A, not applicable; NfHSMI34, NfH detected with
SMI34 antibody; NfHSMI35, NfH detected with SMI35 antibody; OND, other neurological diseases; PP, primary progressive; RR, relapsing remitting; SP,
secondary progressive.
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MS. A significantly higher proportion of these patients had
SP/PP than RR disease. Additionally, the median NfHSMI35follow up
level was significantly higher in SP/PP rather than in RR
disease. The marked increase of NfHSMI34 levels suggests that
NfH phosphorylation may increase with disease duration.
This interpretation contrasts with the consistent immunocy-
tochemical observation that injured and demyelinated axons
stain for non-phosphorylated NfH (NfHSMI32).2 29–32 However,
none of these studies presented quantitative data comparing
the number of axons staining for phosphorylated versus non-
phosphorylated NfH. A further complicating factor is that
proteolytic enzyme activity is a prominent feature of the MS
plaque33 34 and potentially affects the levels, particularly of
non-phosphorylated NfH, which is susceptible to proteoly-
sis.24–26 To address this question we are currently analys-
ing the quantitative distribution of NfH phosphoforms
(NfHSMI32, NfHSMI34, and NfHSMI35) in microdissected brain
tissue homogenates from a previously published cohort.17 35 36
An increase in NfH phosphorylation supports our finding and
can be explained by targeted phosphorylation of the KSP
repeats of the NfH and NfM tail domains by ERK1/2.37 Fibrin
upregulates ERK1/238 and has shown to be deposited on
injured axons.35 36 39 Additionally the mitogen activated
protein (MAP) kinases SAPKs and ERK1/2 are activated by
glutamate40–44 which in turn leads to Ca influx, slowing of
axonal Nf transport, and increased Nf phosphorylation.45 46
Glutamate toxicity is an important pathological feature in
MS, metabotropic glutamate receptor group I alpha is
upregulated on axons in MS29 and experimental treatment
with the AMPA/kainate antagonist NBQX reduces axonal
damage in experimental autoimmune encephalomyelitis.30
The present CSF results are also consistent with the
postmortem observation that axonal damage increases with
time in SP/PPMS patients,47 with additional support from
brain imaging48 and epidemiological studies.28
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Figure 1 (A) CSF NfHSMI35 levels and (B) CSF NfHSMI34 levels in
patients with relapsing remitting (RR) and secondary/primary
progressive (SP/PP) forms of multiple sclerosis (MS). A significantly
higher proportion of patients with SP/PPMS (13/22) had an increase in
CSF NfHSMI35 levels between baseline and follow up (straight lines) when
compared with patients with RRMS (1/7, p,0.05, Fisher’s exact test).
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Figure 2 Correlation between the CSF NfHSMI35 levels and (A) the
Expanded Disability Status Scale (EDSS), (B) the ambulation index (AI),
and (C) the 9HPT (nine hole peg test; log transformed scale) at follow up.
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Secondly, we found a correlation between CSF NfHSMI35
and three clinical scales. This finding indirectly confirms two
previous reports on a different Nf subunit (the 68 kDa light
chain, NfL).12 13 Lycke et al reported CSF NfL correlated with
the EDSS at baseline (r=0.27) and follow up (r=0.34) in
patients with RRMS.12 Semra et al found CSF NfL correlated
with the EDSS (r=0.41) in patients progressive MS.13
However, no such correlations were found at baseline in
our original study,18 the present follow up cohort, or a recent
study on patients with RRMS and SPMS.49 Because clinically,
some of our patients with SP/PP disease improved a degree of
disability at baseline, it is likely that conduction block and
demyelination which are, in contrast to axonal loss,
reversible, contributed to the deficit.
Thirdly, a tendency for higher median CSF NfHSMI35baseline and
NfHSMI34baseline levels were observed in those patients with MS
who progressed clinically on the EDSS scale. This was most
marked for patients with RR disease and suggests that axonal
damage during the course of MS is a poor prognostic feature.
However, the study failed to show statistical difference. The
high positive predictive value and sensitivity suggest that
this might be due to the small sample size. It is important to
note that axonal loss is not the dominant pathological fea-
ture in MS compared with other neurological diseases.23 50
Nevertheless, the demonstrated slow accumulation of axonal
loss seems a logical explanation for the development of
sustained disability in the progressive course of the disease.
When interpreting the present data one needs to consider
that the patient group is population based and the numbers
small. Clinically, there was no significant change in the EDSS
of the patients with SP/PPMS within three years. This
represents a benign course compared with the more rapid
progression observed in other cohorts of patients selected
from hospital populations. Additionally the low median CSF
NfHSMI35 level of the RRMS cohort at follow up would
suggest that these patients might have a benign disease
course. The results must be interpreted with caution and will
need to be cross-validated in other longitudinal studies with
different cohorts of patients.
Taking all these observations together, the results of the
present study are in accordance with the current concept of
progressive axonal degeneration in MS which is based on
evidence from animal,51 52 human postmortem,2 3 5 36 47 53
magnetic resonance spectroscopy,54 magnetic resonance
imaging,7–9 55 and epidemiological studies.28 56
In conclusion, the findings of our prospective three year
study support the idea that CSF NfH phosphoforms might be
valuable surrogate markers which have the potential to be
used as new secondary outcome measures in trials of MS
treatment.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
A Petzold, G Keir, D Grant, E J Thompson, G Giovannoni, Institute of
Neurology, Department of Neuroinflammation, London, UK
M J Eikelenboom, R H C Lazeron, C H Polman, B M J Uitdehaag,
Department of Neurology, VU Medical Center, Amsterdam, the
Netherlands
This study was devised as part of a study into biomarkers for
neurodegeneration supported by the Multiple Sclerosis Society of
Great Britain and Northern Ireland (AP, GG), the BR Kirk Fund of the
Institute of Neurology (AP, ET), and the Multiple Sclerosis Society of the
Netherlands (JE).
Competing interests: none declared
During the review process of this paper a separate study on the
cerebrospinal neurofilament phosphoforms (NfHSMI34 and NfHSMI35)
was published by Lim ET, Grant D, Pashenkov M, et al. Cerebrospinal
fluid levels of brain specific proteins in optic neuritis. Mult Scler
2004;10:261–5.
REFERENCES
1 Waxman SG. Nitric oxide and the axonal death cascade. Ann Neurol
2003;53:150–3.
2 Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of
multiple sclerosis. N Engl J Med 1998;338:278–85.
3 Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple
sclerosis lesions. Brain 1997;120:393–9.
4 Bitsch A, Schuchard J, Bunkowski S, et al. Acute axonal injury in multiple
sclerosis: correlation with demyelination and inflammation. Brain
2000;123:1174–83.
5 Bjartmar C, Kinkel RP, Kidd G, et al. Axonal loss in normal-appearing white
matter in a patient with acute MS. Neurology 2001;57:1248–52.
6 Kapoor R, Davies M, Blaker PA, et al. Blockers of sodium and calcium entry
protect axons from nitric oxide-mediated degeneration. Ann Neurol
2003;53:174–80.
7 Losseff NA, Webb SL, O’Riordan JI, et al. Spinal cord atrophy and disability
in multiple sclerosis. A new reproducible and sensitive MRI method with
potential to monitor disease progression. Brain 1996;119:701–8.
8 Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple
sclerosis: a serial MRI study. Brain 1996;119:2009–19.
9 Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting
multiple sclerosis: fractional volumetric analysis of gray matter and white
matter. Radiology 2001;220:606–10.
10 Zhai Q, Wang J, Kim A, et al. Involvement of the ubiquitin-proteasome system
in the early stages of Wallerian degeneration. Neuron 2003;39:217–25.
11 Griffin JW, George EB, Hsieh ST, et al. Axonal degeneration and disorders of
the axonal cytoskeleton. In: Waxman SG, Kocsis JD, Stys PK, eds. The axon:
structure, function and pathophysiology. New York, Oxford: Oxford
University Press, 1995:375–90.
12 Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in
cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol
Neurosurg Psychiatry 1998;64:402–4.
13 Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal
cytoskeletal proteins in multiple sclerosis is associated with progressive disease
and clinical disability. J Neuroimmunol 2002;122:132–9.
14 McDonald WI. Relapse, remission, and progression in multiple sclerosis.
N Engl J Med 2000;343:1486–7.
15 Waxman SG. Demyelinating diseases—new pathological insights, new
therapeutic targets. N Engl J Med 1998;338:323–5.
16 Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis
lesions: implications for the pathogenesis of demyelination. Ann Neurol
2000;47:707–17.
17 Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell
responses in multiple sclerosis: clinical and pathological correlations. Brain
2002;125:1462–73.
18 Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis:
neurofilament light chain antibodies are correlated to cerebral atrophy.
Neurology 2003;60:219–23.
19 McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria
for multiple sclerosis: guidelines from the international panel on the diagnosis
of multiple sclerosis. Ann Neurol 2001;50:121–7.
Table 3 CSF levels and ratio of NfH phosphoforms for clinically progressive versus stable
patients at baseline. Values are median (interquartile range)
MS (all patients) SP/PP RR
Stable Progressive Stable Progressive Stable Progressive
Number 19 15 16 7 3 8
NfHSMI35
(pg/ml) 38 (17–155) 107 (49–163) 42 (24–173) 104 (78–173) 5 (0–53) 115 (43–165)
NfHSMI34
(pg/ml) 11 (5–13) 8 (5–14) 11 (7.5–13.0) 9 (5–16) 2 (0–5) 7.5 (6–11)
Ratio 3.2 (0.6–5.8) 1.0 (0.4–3.5) 3.2 (0.6–6.0) 1.1 (0.5–1.7) 2.5 (0.9–4.0) 0.9 (0.4–3.5)
See table 2 for abbreviations.
210 Petzold, Eikelenboom, Keir, et al
www.jnnp.com
20 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis:
results of an international survey National Multiple Sclerosis Society (USA)
Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Neurology 1996;46:907–11.
21 Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded
disability status scale (EDSS). Neurology 1983;33:1444–52.
22 Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association
between disability and biological markers in MS. Neurology
2001;57:1253–8.
23 Petzold A, Keir G, Green AJE, et al. A specific ELISA for measuring
neurofilament heavy chain phosphoforms. J Immunol Methods
2003;278:179–90.
24 Sternberger LA, Sternberger NH. Monoclonal antibodies distinguish
phosphorylated and non phosphorylated forms of neurofilaments in situ. Proc
Natl Acad Sci U S A 1983;82:6126–30.
25 Goldstein ME, Sternberger NH, Sternberger LA. Phosphorylation protects
neurofilaments against proteolysis. J Neuroimmunol 1987;14:149–60.
26 Pant HC. Dephosphorylation of neurofilament proteins enhances their
susceptibility to degradation by calpain. Biochem J 1988;256:665–8.
27 McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple
sclerosis. Neuropathol Appl Neurobiol 1992;18:319–34.
28 Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of
disability in multiple sclerosis. N Engl J Med 2000;343:1430–8.
29 Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II
metabotropic glutamate receptors in multiple sclerosis. Brain
2003;126:1755–66.
30 Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple
sclerosis. Nat Med 2000;6:67–70.
31 Gilgun-Sherki Y, Panet H, Melamed E, et al. Riluzole suppresses experimental
autoimmune encephalomyelitis: implications for the treatment of multiple
sclerosis. Brain Res 2003;989:196–204.
32 Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis
in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol
2001;50:169–80.
33 Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood
leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol
1978;4:337–44.
34 Adams CW. The onset and progression of the lesion in multiple sclerosis.
J Neurol Sci 1975;25:165–82.
35 Gveric D, Hanemaaijert R, Newcombe J, et al. Plasminogen activators in
multiple sclerosis lesions: implications for the inflammatory response and
axonal damage. Brain 2001;124:1978–88.
36 Gveric D, Herrera B, Petzold A, et al. Impaired fibrinolysis in multiple
sclerosis: a role for tissue plasminogen activator inhibitors. Brain
2003;126:1590–8.
37 Grant P, Pant HC. Neurofilament protein synthesis and phosphorylation.
J Neurocytol 2000;29:843–72.
38 Akassoglou K, Yu WM, Akpinar P, et al. Fibrin inhibits peripheral nerve
remyelination by regulating Schwann cell differentiation. Neuron
2002;33:861–75.
39 Akassoglou K, Kombrinck KW, Degen JL, et al. Tissue plasminogen activator-
mediated fibrinolysis protects against axonal degeneration and demyelination
after sciatic nerve injury. J Cell Biol 2000;149:1157–66.
40 Brownlees J, Yates A, Bajaj NP, et al. Phosphorylation of neurofilament heavy
chain side-arms by stress activated protein kinase-1b/jun n-terminal kinase-3.
J Cell Sci 2000;113:401–7.
41 Kurino M, Fukunaga K, Ushio Y, et al. Activation of mitogen-activated protein
kinase in cultured rat hippocampal neurons by stimulation of glutamate
receptors. J Neurochem 1995;65:1282–9.
42 Schwarzschild MA, Cole RL, Meyers MA, et al. Contrasting calcium
dependencies of SAPK and ERK activations by glutamate in cultured striatal
neurons. J Neurochem 1999;72:2248–55.
43 Schwarzschild MA, Cole RL, Hyman SE. Glutamate, but not dopamine,
stimulates stress-activated protein kinase and AP-1-mediated transcription in
striatal neurons. J Neurosci 1997;17:3455–66.
44 Xia Z, Dudek H, Miranti CK, et al. Calcium influx via the NMDA receptor
induces immediate early gene transcription by a MAP kinase/ERK-dependent
mechanism. J Neurosci 1996;16:5425–36.
45 Ackerley S, Grierson AJ, Brownlees J, et al. Glutamate slows axonal transport
of neurofilaments in transfected neurons. J Cell Biol 2000;150:165–76.
46 Ackerley S, Thornhill P, Grierson AJ, et al. Neurofilament heavy chain side
arm phosphorylation regulates axonal transport of neurofilaments. J Cell Biol
2003;161:489–95.
47 Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple
sclerosis is most extensive in early disease stages and decreases over time.
Brain 2002;125:2202–12.
48 Barkhof F. The clinico-radiological paradox in multiple sclerosis. Curr Opin
Neurol 2002;15:239–45.
49 Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein
and glial fibrillary acidic protein as biological markers in MS. Neurology
2003;61:1720–5.
50 Petzold A, Hinds N, Keir G, et al. CSF neurofilament protein levels predict the
primary pathology (axonal versus demyelinating) in Guillain–Barre´ syndrome.
J Neurol Sci 2002;199(suppl 1):S119.
51 Petzold A, Baker D, Pryce G, et al. Quantification of neurodegeneration by
measurement of brain-specific proteins. J Neuroimmunol 2003;138:45–8.
52 Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration
in models of multiple sclerosis. Brain 2003:2191–202.
53 Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic
autoimmune encephalomyelitis: a comparative quantitative study of axonal
injury in active, inactive, and remyelinated lesions. Am J Pathol
2000;157:267–76.
54 van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in
multiple sclerosis lesions: magnetic resonance imaging insights into substrates
of disability. Ann Neurol 1999:747–54.
55 Truyen L, van Waesberghe JH, van Waldervaan MA, et al. Accumulation of
hypointense lesions (‘‘black holes’’) on T1 spin echo MRI correlates with
disease progression in multiple sclerosis. Neurology 1996;47:1469–76.
56 Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence
cohort with twenty-five years of follow-up. Brain 1993;116:117–34.
Accumulated axonal damage in MS 211
www.jnnp.com
